ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure

Key Takeaways

• First commercial FLIGHT procedures performed in London and Düsseldorf
• ViaLuxe system merges OCT imaging with femtosecond laser for micron precision
• Incision‑free laser creates trabecular meshwork channels to lower IOP
• ViaLase signs exclusive UK distribution deal with Carleton Optical
• Glaucoma prevalence expected to rise to 112 million worldwide by 2040

Pulse Analysis

ViaLase’s commercial introduction of the FLIGHT procedure marks a pivotal moment for glaucoma therapeutics. By leveraging the ViaLuxe Laser System’s high‑resolution OCT imaging and femtosecond laser precision, the treatment delivers micron‑level channels through the trabecular meshwork without any incision. This technology not only reduces intra‑ocular pressure but also eliminates the need for traditional surgical entry, offering a patient‑centric experience that aligns with the broader shift toward minimally invasive ophthalmic procedures.

The global burden of glaucoma is projected to climb from 76 million today to over 112 million by 2040, intensifying demand for safer, earlier‑stage interventions. Current care pathways rely heavily on topical drops, laser trabeculoplasty, and MIGS devices, each with adherence challenges or procedural risks. FLIGHT’s incision‑free, image‑guided approach could fill a critical gap by providing clinicians a precise, repeatable method to restore outflow before disease progression necessitates more invasive surgery, potentially reshaping reimbursement models and accelerating adoption in high‑volume eye‑care centers.

Regulatory realities shape ViaLase’s market strategy: while the ViaLuxe system remains investigational in the United States, it is fully commercialized across Europe, supported by an exclusive UK distributor, Carleton Optical. The company’s partnership with renowned surgeons in London and Düsseldorf underscores a credibility boost that may expedite payer acceptance. Looking ahead, successful European uptake could pave the way for U.S. clinical trials, positioning ViaLase as a frontrunner in the next generation of glaucoma care and prompting competitors to explore similar non‑invasive laser platforms.